<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04326283</url>
  </required_header>
  <id_info>
    <org_study_id>CT1SNR1611ALS1</org_study_id>
    <nct_id>NCT04326283</nct_id>
  </id_info>
  <brief_title>Trial of Safety, Tolerability and Efficacy of Trametinib (SNR1611) in Patients With Amyotrophic Lateral Sclerosis (ALS)</brief_title>
  <official_title>A Sequential Dose-Escalation, Randomized, Active-Controlled, Multi-Center, Phase 1/2a Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of SNR1611 in Patients With Amyotrophic Lateral Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genuv Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genuv Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability and efficacy of trametinib
      (SNR1611) in the treatment of amyotrophic lateral sclerosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Trametinib (SNR1611) is a MEK inhibitor that downregulates the MAPK/ERK pathway. In this
      study, the potential of MAPK/ERK pathway downregulation through trametinib (SNR1611) as a
      therapeutic treatment for amyotrophic lateral sclerosis (ALS) will be evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 2, 2020</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients will be randomly assigned 4:1 to receive SNR1611 (0.5, 1 or 2 mg) or riluzole as an active comparator. The study will initiate with the first group of patients who will receive SNR1611 (0.5 mg, 8 patients) or riluzole (100 mg, 2 patients), while the initiation of the next dose groups will be decided by the IDMC (Independent Data Monitoring Committee) through safety assessment of the first 4-week periods of prior dose groups.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>K-ALSFRS-R score will be measured by independent outcome assessors.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of SNR1611: adverse events</measure>
    <time_frame>24-week (additional 24-week is optional)</time_frame>
    <description>Observation of adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>K-ALSFRS-R score</measure>
    <time_frame>24-week (additional 24-week is optional)</time_frame>
    <description>Change in Korean Amyotrophic Lateral Sclerosis Functional Rating Scale Revised (K-ALSFRS-R) score from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC</measure>
    <time_frame>24-week (additional 24-week is optional)</time_frame>
    <description>Change in Forced Vital Capacity (FVC) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CSF trough concentrations of SNR1611</measure>
    <time_frame>24-week (additional 24-week is optional)</time_frame>
    <description>Trough concentrations of SNR1611 in cerebrospinal fluid (CSF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma trough concentrations of SNR1611</measure>
    <time_frame>24-week (additional 24-week is optional)</time_frame>
    <description>Trough concentrations of SNR1611 in plasma</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>Trametinib (0.5 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One tablet of trametinib 0.5 mg per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Trametinib (1 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two tablets of trametinib 0.5 mg per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Trametinib (2 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One tablet of trametinib 2 mg per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Riluzole (100 mg)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One tablet of riluzole 50 mg taken twice per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trametinib (0.5 mg)</intervention_name>
    <description>0.5 mg/day</description>
    <arm_group_label>Trametinib (0.5 mg)</arm_group_label>
    <other_name>Meqsel</other_name>
    <other_name>SNR1611</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trametinib (1 mg)</intervention_name>
    <description>1 mg/day</description>
    <arm_group_label>Trametinib (1 mg)</arm_group_label>
    <other_name>Meqsel</other_name>
    <other_name>SNR1611</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trametinib (2 mg)</intervention_name>
    <description>2 mg/day</description>
    <arm_group_label>Trametinib (2 mg)</arm_group_label>
    <other_name>Meqsel</other_name>
    <other_name>SNR1611</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Riluzole (100 mg)</intervention_name>
    <description>100 mg/day (50 mg twice)</description>
    <arm_group_label>Riluzole (100 mg)</arm_group_label>
    <other_name>Yooritek</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main inclusion criteria:

          -  Patients diagnosed as definite, probable or probable-laboratory-supported ALS
             according to El Escorial Criteria.

          -  Patients of less than 2 years after the onset of ALS.

          -  Patients who meet the criteria of K-ALSFRS-R score and forced vital capacity.

        Main exclusion criteria:

          -  Patients with primary lateral sclerosis, progressive muscular atrophy or lower motor
             neuron disease.

          -  Patients who have history of ALS treatment of edaravone or stem cell therapy within 16
             weeks before screening.

          -  Patients who have permanently ceased the administration of riluzole due to lack of
             tolerability and/or efficacy.

          -  Patients in Class II to IV according to the New York Heart Association functional
             classification. Patients with myocardial infarction, unstable arrhythmia, and/or
             significant cardiovascular disease such as unstable angina within 12 weeks before
             screening.

          -  Patients who do not meet the criteria of laboratory tests and medical/operation
             history.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Byoung Joon Kim</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center, Seoul, Republic of Korea</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Inho Seo</last_name>
    <phone>+82-2-542-0318</phone>
    <email>info@genuv.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kwang-Kuk Kim</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Byung-Jo Kim</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Byoung Joon Kim</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ha Young Shin</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>March 24, 2020</study_first_submitted>
  <study_first_submitted_qc>March 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2020</study_first_posted>
  <last_update_submitted>July 20, 2020</last_update_submitted>
  <last_update_submitted_qc>July 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ALS</keyword>
  <keyword>Lou Gehrig's disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trametinib</mesh_term>
    <mesh_term>Riluzole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

